Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA ne… Read more
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) - Total Assets
Latest total assets as of June 2025: CN¥1.66 Billion CNY
Based on the latest financial reports, Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) holds total assets worth CN¥1.66 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A - Total Assets Trend (2019–2024)
This chart illustrates how Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's total assets of CN¥1.66 Billion consist of 67.5% current assets and 32.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.7% |
| Accounts Receivable | CN¥34.75 Million | 1.9% |
| Inventory | CN¥41.06 Million | 2.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥149.32 Million | 8.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's current assets represent 67.5% of total assets in 2024, an increase from 48.6% in 2019.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2024, down from 24.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 34.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 8.2% of total assets.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A Competitors by Total Assets
Key competitors of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is currently not profitable relative to its asset base.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 2.25 | 4.24 |
| Quick Ratio | 2.72 | 2.11 | 4.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥703.17 Million | CN¥ 590.04 Million | CN¥ 1.14 Billion |
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.62 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -15.3% |
| Total Assets | CN¥1.81 Billion |
| Market Capitalization | $548.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's assets below their book value (0.30 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's assets decreased by 15.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (2019–2024)
The table below shows the annual total assets of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.81 Billion | -15.33% |
| 2023-12-31 | CN¥2.14 Billion | -11.23% |
| 2022-12-31 | CN¥2.41 Billion | -4.81% |
| 2021-12-31 | CN¥2.53 Billion | +0.29% |
| 2020-12-31 | CN¥2.53 Billion | +168.79% |
| 2019-12-31 | CN¥939.53 Million | -- |